GSK-7975A is a potent, orally available inhibitor of the Calcium Release-Activated Calcium (CRAC) channel.

GSK-7975A inhibits toxin-induced activation of ORAI1 and/or activation of Ca2+ currents after Ca2+ release, in a concentration-dependent manner, in mouse and human pancreatic acinar cells (inhibition >90% of the levels observed in control cells). GSK-7975A inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety species and it also completely inhibits calcium influx through CRAC channels. This leads to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. GSK-7975A decreases FcεRI-dependent Ca2+ influx and 3 μM GSK-7975A decreases the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα) by up to 50%[1]. Mast cells from guinea-pig and mouse preparations are not inhibited by GSK-7975A; however cytokine release is fully blocked from T-cells in a mouse preparation[2]. GSK-7975A also prevents activation of the necrotic cell death pathway in mouse and human pancreatic acinar cells[3].

GSK-7975A obviously decreses increases in serum amylase, IL6, and pancreatic MPO levels; lung MPO is reduced significantly by low dose only. GSK-7975A inhibits local and systemic features of acute pancreatitis in TLCS-AP, CER-AP, FAEE-AP, in dose- and time-dependent manners. GSK-7975A markedly decreases pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP[3].

DMSO: 250 mg/mL (629.25 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.31 mM), Sonication is recommended.